A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

Trial Profile

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs INCB 50465 (Primary) ; Itacitinib (Primary) ; Pembrolizumab
  • Indications Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 14 Aug 2017 Planned number of patients changed from 140 to 201.
    • 02 Feb 2017 Planned number of patients changed from 78 to 140.
    • 02 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top